Form 4: Zimmer Biomet Executive Sells 800 Shares of Common Stock

Sang Yi, Group President of Asia Pacific at Zimmer Biomet Holdings, Inc., reported the sale of 800 shares of company common stock for approximately $74,011.20.

Summary

• Sang Yi, the Group President of Asia Pacific for Zimmer Biomet Holdings, Inc. (ZBH), reported a transaction involving the company's common stock.
• On June 13, 2025, Mr. Yi disposed of 800 shares of ZBH common stock.
• The shares were sold at a price of $92.514 per share.
• The total value of the shares sold amounts to approximately $74,011.20 (800 shares * $92.514/share).
• Following this transaction, Sang Yi directly beneficially owns 19,624 shares of Zimmer Biomet Holdings, Inc. common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to an insider sale, even though it was pre-planned under a 10b5-1 plan. Insider selling, regardless of the reason, can be interpreted as a lack of strong conviction in future stock appreciation.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reactive one, which can mitigate negative interpretations of insider selling.

Negatives

• An insider sale, even if pre-planned, reduces the executive's direct ownership in the company.
• The sale of 800 shares by a Group President could be perceived as a slight negative signal regarding management's immediate outlook on the stock's valuation, despite the 10b5-1 plan.

Risks

• The sale by an insider, particularly an officer, could be interpreted by investors as a lack of confidence in the company's near-term stock performance, potentially leading to negative market sentiment.
• While conducted under a 10b5-1 plan, significant or repeated insider selling could raise questions about the company's future prospects among investors.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction; it is solely a disclosure of an insider stock transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction within the medical device and orthopedics industry. Such filings are common and provide transparency into executive stock ownership changes, which can sometimes be interpreted by the market as signals about the company's internal outlook. Zimmer Biomet is a major player in this sector.

Related Party Transactions

• The sale of 800 shares of Zimmer Biomet Holdings, Inc. common stock by Sang Yi, an officer of the company, constitutes a related party transaction as it involves an insider's dealings in the company's securities.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal, potentially influencing their investment decisions or perception of the company's near-term prospects.
• Employees: No direct impact mentioned, but general market sentiment can indirectly affect employee morale or stock-based compensation value.

Key Dates

Recommendation

Keywords

Zimmer Biomet Holdings, ZBH, SEC Form 4, Insider Trading, Stock Sale, Executive Compensation, Medical Devices, Orthopedics, Rule 10b5-1